Stars Shine at Beverly Hills Gala by Beauty-Stem: Advancing Health Innovations and Cancer Research 
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets...
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today...
Dyadic Expands Global Presence with Participation in Key Industry Events
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company...
DAXOR’S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL ’24
Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation...
Auron to Present AUTX-703 Preclinical Data 2024 ENA Symposium
NEWTON, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by...
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
The Company recently announced the positive topline results from the Phase 2b study with istaroxime in acute heart failure patients...
Clene to Present at Upcoming October Conferences
SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...
BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea
BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the...
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel...
Vanqua Bio Announces Positive Interim Results from Phase 1 Clinical Trial of VQ-101, an Orally Administered, Brain-Penetrant, Allosteric Activator of GCase for the Treatment of GBA-Parkinson’s and Related Disorders
VQ-101 is the first small molecule to demonstrate > 75% activation of the lysosomal enzyme glucocerebrosidase (GCase) in humansIn healthy...
ProKidney to Participate in the UBS Virtual Organ Restoration Day
WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the...
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
- Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe...
Chiesi USA Releases 2023 Sustainability Report and Highlights US Community Engagement Strategy Focus Areas
Chiesi 2023 Sustainability Report Chiesi 2023 Sustainability Report 2023 Sustainability Report demonstrates strong impact across Patients, Planet, People and ProsperityUS...
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
Designation is based on data from the clinical development program which demonstrated clinical proof of conceptFelzartamab, an investigational anti-CD38 monoclonal...
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October...
Reunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health Disorders
Reunion to Sponsor Scholarships that will Train Healthcare Professionals on Maternal Mental Health Disorders, including Postpartum Depression Reunion’s Phase 2...
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company...
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving...
Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at 2024 Visceral Medicine Congress
Misetionamide-gemcitabine combination demonstrates very good safety profile and potential therapeutic benefit in the challenging treatment of pancreatic adenocarcinoma Interim results...
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
– Additional positive data from the Company’s completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports...